Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD study of PF-05230907 in healthy Japanese subjects
NCT02537002Phase 1Completed
- Sponsor
- Pfizer
- Start
- Sep 2015
- Primary completion
- Mar 2016
- Modality
- Blood Coagulation Factors
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PF-05230907 in intracerebral hemorrhage (ICH) (2 cohorts), sponsored by Pfizer. Primary endpoint: Incidence of Adverse Events and Serious Adverse Events Per Participant up to 2 months. Started Sep 2015; status: completed.
02
Drugs
PF-05230907
03
Conditions
intracerebral hemorrhage (ICH)
Beyond the preview
Go deeper on NCT02537002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02537002.